Differential Effects of Opiate Peptides and Alkaloids on Anterior Pituitary Hormone Secretion

1983 ◽  
Vol 37 (4) ◽  
pp. 275-279 ◽  
Author(s):  
Giuseppe Delitala ◽  
Ashley Grossman ◽  
Michael Besser
Keyword(s):  
Anterior Pituitary ◽  
Hormone Secretion ◽  
Pituitary Hormone ◽  
Differential Effects ◽  
Anterior Pituitary Hormone ◽  
Opiate Peptides

Vasopressin as a neuroendocrine regulator of anterior pituitary hormone secretion

1993 ◽  
Vol 129 (6) ◽  
pp. 489-496 ◽  
Author(s):  
Andreas Kjær
Keyword(s):  
Arginine Vasopressin ◽  
Mode Of Action ◽  
Anterior Pituitary ◽  
Hormone Secretion ◽  
Pituitary Hormones ◽  
Pituitary Hormone ◽  
Anterior Pituitary Hormones ◽  
Anterior Pituitary Hormone

Secretion of the anterior pituitary hormones adrenocorticotropin (ACTH), β-endorphin and prolactin (PRL) is complex and involves a variety of factors. This review focuses on the involvement of arginine-vasopressin (AVP) in neuroendocrine regulation of these anterior pituitary hormones with special reference to receptor involvement, mode of action and origin of AVP. Arginine-vasopressin may act via at least two types of receptors: V1− and V2−receptors, where the pituitary V1−receptor is designated V1b. The mode of action of AVP may be mediating, i.e. anterior pituitary hormone secretion is transmitted via release of AVP, or the mode of action may be permissive, i.e. the presence of AVP at a low and constant level is required for anterior pituitary hormones to be stimulated. Under in vivo conditions, the AVP-induced release of ACTH and β-endorphin is mainly mediated via activation of hypothalamic V1− receptors, which subsequently leads to the release of corticotropin-releasing hormone. Under in vitro conditions, the AVP-stimulated release of ACTH and β-endorphin is mediated via pituitary V1b− receptors. The mode of action of AVP in the ACTH and β-endorphin response to stress and to histamine, which is involved in stress-induced secretion of anterior pituitary hormones, is mediating (utilizing V1− receptors) as well as permissive (utilizing mainly V1− but also V2−receptors). The AVP-induced release of PRL under in vivo conditions is conveyed mainly via activation of V1−receptors but V2−receptors and probably additional receptor(s) may also play a role. In stress- and histamine induced PRL secretion the role of AVP is both mediating (utilizing V1 −receptors) and permissive (utilizing both V1− and V2− receptors). Arginine-vasopressin may be a candidate for the PRL-releasing factor recently identified in the posterior pituitary gland. Arginine-vasopressin of both magno- and parvocellular origin may be involved in the regulation of anterior pituitary hormone secretion and may reach the corticotrophs and the lactotrophs via three main routes: the peripheral circulation, the long pituitary portal vessels or the short pituitary portal vessels.

The effects on anterior pituitary hormone secretion of salmon calcitonin in healthy volunteers

1991 ◽  
Vol 34 (4) ◽  
pp. 299-304 ◽  
Author(s):  
P. J. Trainer ◽  
J. M. W. Kirk ◽  
L. McLoughlln ◽  
R. J. Touzel ◽  
L. Perry ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Salmon Calcitonin ◽  
Anterior Pituitary ◽  
Hormone Secretion ◽  
Pituitary Hormone ◽  
Anterior Pituitary Hormone

The effect of Low-Dose Dopamine Infusion on Anterior Pituitary Hormone Secretion in Normal Female Subjects

1984 ◽  
Vol 67 (2) ◽  
pp. 219-223 ◽  
Author(s):  
J. M. C. Connell ◽  
S. G. Ball ◽  
G. C. Inglis ◽  
G. H. Beastall ◽  
D. L. Davies
Keyword(s):  
Anterior Pituitary ◽  
Low Dose ◽  
Hormone Secretion ◽  
Serum Prolactin ◽  
Control Group ◽  
Pituitary Hormone ◽  
Normal Female ◽  
Dopamine Infusion ◽  
Anterior Pituitary Hormone ◽  
Female Subjects

1. The effect of low-dose dopamine infusion on anterior pituitary hormone secretion in a group of seven healthy female subjects is reported. Subjects were infused with NaCl solution (154 mmol/l) (control) or dopamine (0.01 and 0.1 μg min−1 kg−1 for 120 min at each rate) on separate days in the early follicular phase of consecutive menstrual cycles. 2. Serum prolactin decreased during infusion of dopamine at 0.01 μg min−1 kg−1 but a similar fall was found in the control group. 3. When the rate of dopamine infusion was increased to 0.1 μg min−1 kg−1 a further substantial decrease in prolactin concentration occurred, whereas prolactin in the control group showed no change. At the end of the period of dopamine infusion at 0.1 μg min−1 kg−1 serum prolactin remained significantly (P<0.025) lower than in the control group (85 ± 12 vs 180 ± 21 m-units/l). 4. No change in thyrotrophin (TSH), growth hormone (GH) or luteinizing hormone (LH) was seen during either rate of dopamine infusion compared with control. 5. While dopamine infusion at 0.1 μg min−1 kg−1 caused significant inhibition of prolactin secretion in normal female subjects, other pituitary hormone secretion was not affected: it is suggested that under the conditions of this study dopamine in hypophysial portal blood is not of primary importance in the control of basal TSH, GH and LH release.

Paracrine control of anterior pituitary hormone secretion

1990 ◽  
Vol 127 (1) ◽  
pp. 5-13 ◽  
Author(s):  
T. H. Jones ◽  
B. L. Brown ◽  
P. R. M. Dobson
Keyword(s):  
Anterior Pituitary ◽  
Hormone Secretion ◽  
Pituitary Hormone ◽  
Anterior Pituitary Hormone

Effect of exogenous β-endorphin on anterior pituitary hormone secretion in man

1982 ◽  
Vol 99 (1) ◽  
pp. 9-13 ◽  
Author(s):  
Tsutomu Oyama ◽  
Ryuji Yamaya ◽  
Toshiro Jin ◽  
Tsuyoshi Kudo
Keyword(s):  
Growth Hormone ◽  
Anterior Pituitary ◽  
Human Subjects ◽  
Hormone Secretion ◽  
Plasma Concentrations ◽  
Adrenocortical Function ◽  
Control Group ◽  
Pituitary Hormone ◽  
Plasma Acth ◽  
Anterior Pituitary Hormone

Abstract. The effect of large amounts of synthesized human β-endorphin (β-Ep) administered intrathecally on pituitary-adrenocortical function was investigated by determining the plasma levels of ACTH, cortisol, growth hormone and prolactin in 8 patients with pain caused by severe disseminated cancer. They were divided into 2 groups, an Ep group of 8 patients and a control group of 5 of the same 8 patients. There were no significant effects of β-Ep on plasma ACTH, cortisol and growth hormone levels. However, the injection of β-Ep into human subjects resulted in a rise in plasma concentrations of prolactin.

Sign in / Sign up

Export Citation Format

Share Document